Company

Our work

Voronoi develops novel TPD (Target protein degraders) and kinase inhibitors with the aim to treat intractable and rare diseases. We are developing competitive therapies based on deep understanding of diseases and innovative technologies.

People

Sunghwan Kim, PhD

(Korean) 보로노이는 글로벌 제약사와 견줄 수 있는 연구 역량과 기술력을 확보해 나아가고 있습니다.